Late-Breaking Advances in IgAN

Jonathan Barratt, PhD, is a professor and lead of the renal research group at the University of Leicester. He co-authored several ASN Kidney Week abstracts, including late-breaking presentations on IgA nephropathy. Here, he speaks with Joel Topf, MD, about advances in the IgAN treatment landscape, including results of the ORIGIN study of atacicept and of IGNAZ study of felzartamab.